Loading
Infectious Diseases and Tuberculosis · Journal article
Clinical Medicine · August 1, 2026
A consensus or society position rather than new primary data.
This is a clinical overview of TB epidemiology and management advances, not a systematic evidence synthesis or primary study. It documents that rapid PCR and whole genome sequencing are now standard diagnostic tools, and that shorter treatment regimens are available, but does not quantify their efficacy or compare outcomes against prior standards.
Journal article. Global population affected by TB; clinical focus on UK presentations, including extrapulmonary disease.. UK emphasis, global epidemiology referenced..
Approximately 10.7 million people worldwide were estimated to have developed TB in 2024. TB rates have increased in the UK over the last 3 years. Rapid PCR is now the standard for timely case identification.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
Clinicians should maintain high vigilance for TB across medical subspecialties and acute care settings, particularly for extrapulmonary presentations. Rapid PCR and WGS are now standard tools; clinicians should familiarize themselves with evolving shorter treatment regimens for latent, active, and multidrug-resistant TB.
A narrative review summarizing epidemiological trends, diagnostic advances, and treatment evolution in TB, intended to inform clinical practice rather than present new primary evidence.
As stated by the source record.
Quoted from the source exactly as published.
Clinicians should maintain high vigilance for TB across medical subspecialties and acute care settings, particularly for extrapulmonary presentations. Rapid PCR and WGS are now standard tools; clinicians should familiarize themselves with evolving shorter treatment regimens for latent, active, and multidrug-resistant TB.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Tuberculosis (TB) is the deadliest leading infectious disease globally. Approximately 10.7 million people worldwide were estimated to have developed TB in 2024. TB rates have increased in the UK over the last 3 years. Vigilance in acute care settings and across medical subspecialties is essential to ensure early recognition and control of TB particularly given the significant proportion of extrapulmonary presentations. Advances in diagnostic tools have significantly improved detection, with rapid PCR now becoming the standard for timely case identification. Whole genome sequencing (WGS) is now routinely in place to identify drug resistance, track transmission and guide public health responses. In parallel, treatment strategies are evolving, with shorter and more effective regimens available for latent TB, active disease, and multidrug-resistant TB. This review provides an overview of the epidemiology, clinical presentation, diagnosis, and management of TB, with a focus on recent advances relevant to clinical practice in the UK.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.